BRAF and hepatocellular carcinoma: Sorafenib, an inhibitor of wild-type and V600E-mutant BRAF (V-Raf Murine Sarcoma Viral Oncogene Homolog B), as well as other receptor tyrosine kinases such as VEGFR, has been approved for use in metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma refractory to radioactive iodine treatment (16, 17, 18).